# Darzalex Faspro (daratumumab and hyaluronidase-fihj) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj

> The FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), sponsored by JOHNSON & JOHNSON (JNJ), on May 1, 2020.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Darzalex Faspro (daratumumab and hyaluronidase-fihj) |
| Codes |  |
| Sponsor | JOHNSON & JOHNSON (JNJ) https://sec-api.dev/companies/jnj/catalysts |
| Indications |  |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### May 1, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761145 ORIG-1 (Type 3 - New Dosage Form and Type 4 - New Combination): submission_status AP, submission_status_date 20200501, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22

### January 11, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761145 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20210111, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22
- openFDA Drugs@FDA: "BLA761145 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20210115, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22

### July 9, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761145 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20210709, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22

### November 30, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761145 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20211130, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22

### July 30, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761145 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20240730, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22

### May 20, 2025: FDA advisory committee meeting

- Status: completed. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "On the afternoon of May 20, 2025, the Committee will discuss sBLA 761145/S-029, for DARZALEX FASPRO (daratumumab and hyaluronidase) injection, for subcutaneous use, submitted by Janssen Biotech, Inc. The proposed indication (use) is as monotherapy for the treatment of adult patients with high-risk smoldering multiple myeloma (SMM)." https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025

### November 6, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761145 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20251106, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22

### November 19, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761145 SUPPL-32 (Efficacy): submission_status AP, submission_status_date 20251119, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22

### January 27, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761145 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20260127, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761145%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Darzalex Faspro (daratumumab and hyaluronidase-fihj) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj

```bibtex
@misc{secapidev_pdufa_daratumumab_and_hyaluronidase_fihj_20261116,
  title        = {Darzalex Faspro (daratumumab and hyaluronidase-fihj) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_daratumumab_and_hyaluronidase_fihj_20261116","title":"Darzalex Faspro (daratumumab and hyaluronidase-fihj) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/daratumumab-and-hyaluronidase-fihj","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
